The new genetics: Psychological responses to genetic testing

British Medical Journal

Volumn 316, Issue 7132, 1998, Pages 693-696

  Marteau, Theresa M ^a   Croyle, Robert T ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; DECISION MAKING; GENETIC SCREENING; GOOD CLINICAL PRACTICE; HUMAN; HUNTINGTON CHOREA; MOOD; OVARY CANCER; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SHORT SURVEY; SOCIAL SUPPORT;

EID: 0032574154     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.316.7132.693     Document Type: Short Survey

References (34)

1. Croyle RT, ed. Psychosocial effects of screening for disease prevention and detection. New York: Oxford University Press, 1995.
2. Bell J. Genetic advances: implications for clinical medicine. BMJ 1998;316:618-20.
3. Craufurd D, Dodge A, Kerzin-Storrar L, Harris R. Uptake of presymptomatic predictive testing for Huntington's disease. Lancet 1989;i:603-5.
4. Quaid KA, Morris M. Reluctance to undergo predictive testing: the case of Huntington disease. Am J Med Genet 1993;45:42-5.
5. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996;275:1885-92.
6. Evans DGR, Maher ER, Maclead R, Davies DR, Craufurd D. Uptake of genetic testing for cancer predisposition - ethical issues. J Med Genet 1997;34:746-9.
7. Tambor ES, Bernhardt BA, Chase GA, Faden RR, Geller G, Hofman KJ, et al. Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Am J Hum Genet 1994;55:626-37.
8. Bekker H, Modell M, Dennis G, Silver A, Mathew C, Bobrow M, et al. Uptake of cystic fibrosis carrier testing in primary care: supply push or demand pull? BMJ 1993;306:1584-6.
9. Struewing JP, Lerman C, Kase RG, Giambarresi TR, Tucker MA. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev 1995;4;169-73.
10. Marteau TM, Kidd J, Cook R, Michie S, Johnston M, Slack J, et al. Perceived risk not actual risk predicts uptake of amniocentesis. Br J Obstet Gynaecol 1991;98:282-6.
11. Tibben A, Frets PG, van den Kamp JJP, Niermeijer MF, Vegter-van der Vlis M, Roos RAC, et al. On attitudes and appreciation 6 months after predictive DNA test for Huntington disease in the Dutch program. Am J Med Genet 1993;48:103-11.
12. Marteau TM, Dundas R., Axworthy D. Long term cognitive and emotional impact of genetic testing for carriers of cystic fibrosis: the effects of gender and test result. Health Psychol 1997;16:51-62.
13. Wiggins S, Whyte P, Huggins M, Adam S, Theilmann J, Bloch M, et al. The psychological consequences of predictive testing for Huntington's disease. N Engl J Med 1992;1401-5.
14. Croyle RT, Smith KR, Botkin JR, Baty B, Nash J. Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychol 1997;16:63-72.
15. Tibben A, Timman R, Bannink EC, Duivenvoorden HJ. Three-year follow-up after presymptomatic testing for Huntington's disease in tested individuals and partners. Health Psychol 1997;16:48-63.
16. Lynch HT, Watson P, Conway TA, Lynch JF, Slominski-Caster SM, Narod SA, et al. DNA screening for breast/ovarian cancer susceptibility based on linked markers. Arch Intern Med 1993;153:1979-87.
17. Marteau T, Anionwu E. Evaluating carrier testing: objectives and outcomes. In: Marteau TM, Richards M, eds. The troubled helix: social and psychological implications of the new human genetics. Cambridge: Cambridge University Press, 1996:123-39.
18. Marteau TM, Kidd J, Cook R, Johnston M, Michie S, Shaw RW, et al. Screening for Down's syndrome [letter]. BMJ 1988;297:1469.
19. Watson EK, Mayall E, Chapple J, Dalziel M, Harrington K, Williams C, et al. Screening for carriers of cystic fibrosis through primary health care services. BMJ 1991;303:504-7.
20. Lazarus RS, Folkman S. Stress, appraisal and coping. New York: Springer, 1984.
21. Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Cassiman JJ, Cloostermans T, Demyttenaere K. Prediction of psychological functioning one year after the predictive test for Huntington's disease and impact of the test result on reproductive decision making. J Human Genet 1996;33:737-43.
22. Marteau TM, Senior V. Illness representations after the human genome project: the perceived role of genes in causing illness. In: Petrie K, Weinman J, eds. Perceptions of illness and treatment: current psychological research and implications. Amsterdam: Harwood Academic Press, 1997:241-66.
23. Skinner EA. Personality processes and individual differences: A guide to constructs of control. J Pen Soc Psychol 1996;71:549-70.
24. Lerman C, Gold K, Audrain J, Lin TH, Boyd NR, Orleans CT, et al. Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change. Health Psychol 1997;16:87-99.
25. Bobbio M, Demichelis B, Giustetto G. Completeness of reporting trial results: effects on physicians willingness to prescribe. Lancet 1994;343:1209-11.
26. Bucher HC, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ 1994;309:761-4.
27. Allanson A, Michie S, Marteau TM. Presentation of screen negative results on serura screening for Down syndrome: variations across Britain. J Med Screening 1997;4:21-2.
28. Marteau TM, Plenicar M, Kidd J. Obstetricians presenting amniocentesis to pregnant women: practice observed. J Reprod Infant Psychol 1993;11:3.
29. Hallowell N, Statham H, Murton F, Green J, Richards MPM. "Talking about chance": the presentation of risk information during genetic counseling for breast and ovarian cancer. J Genet Counseling 1997;6:269-86.
30. Klein WM. Objective standards are not enough: affective, self-evaluative behavioral responses to social comparison information. J Pers Soc Psychol 1997;72:763-74.
31. Tibben A, Vegter-van der Vlis M, Niermeijer MF, van der Kamp JJP, Roos RAC, Rooijmans HGM, et al. Testing for Huntington's disease with support for all parties [letter]. Lancet 1990;335:553.
32. Billings PR, Kohn MA. de Cuevas M, Beckwith J, Alper JS, Natowicz MR, Eugenics: past, present and the future. Am J Hum Genet 1991;49:1109-18.
33. Holtzman NA, Shapiro D. Genetic testing and public policy. BMJ (in press).
34. Marteau TM, Drake H. Attributions for disability: the influence of genetic screening. Soc Sci Med 1995;40:1127-32.